Central Serous Chorioretinopathy: An Update on the Current State of Management

Dimitrios Kalogeropoulos; Lincoln Shaw; Dimitra Skondra; Soon Wai Ch'ng; Aikaterini Christodoulou; Chris Kalogeropoulos

doi:10.1055/a-2062-3751

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2024; 241(07): 845-862
DOI: 10.1055/a-2062-3751

Übersicht

Central Serous Chorioretinopathy: An Update on the Current State of Management

Chorioretinopathia centralis serosa: ein Update zum aktuellen Stand der Behandlung

Dimitrios Kalogeropoulos

¹Ophthalmology, University General Hospital of Ioannina, Ioannina, Greece

,

Lincoln Shaw

²Ophthalmology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, United States

,

Dimitra Skondra

²Ophthalmology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, United States

,

Soon Wai Ch'ng

³Ophthalmology, Birmingham and Midland Eye Centre, Birmingham, United Kingdom of Great Britain and Northern Ireland

,

Aikaterini Christodoulou

⁴Ophthalmology, University of Ioannina Faculty of Medicine, Ioannina, Greece

,

Chris Kalogeropoulos

¹Ophthalmology, University General Hospital of Ioannina, Ioannina, Greece

› Author Affiliations

Abstract

Central serous chorioretinopathy (CSCR) is a relatively common retinal disorder that leads to central vision impairment, often with a high recurrence rate. The exact etiology and pathogenetic mechanisms have not been fully elucidated but are likely to be associated with hyperpermeability of the choroidal capillaries and failure of the retinal pigment epithelium (RPE), leading to serous detachment of the neurosensory retina. Multimodal imaging plays a critical role in the diagnostic approach and monitoring of CSCR. Fortunately, the natural course of the disease is usually self-limiting, with spontaneous resolution and total fluid reabsorption. However, some patients may exhibit recurrences or persistent subretinal fluid (chronic CSCR), leading to progressive and irreversible RPE atrophy or photoreceptor damage. Thus, to prevent permanent visual loss, individualized treatment should be considered. Recent developments in the diagnostic and therapeutic approach have contributed to better outcomes in patients with CSCR. More studies are required to improve our understanding of epidemiology, pathogenesis, diagnosis, and treatment, with a significant impact on the management of this challenging clinical entity. The purpose of this review is to summarize the current knowledge about the clinical features, diagnostic workup, and therapeutic approach of CSCR.

Zusammenfassung

Die Chorioretinopathia centralis serosa (CCS) ist eine relativ häufige Netzhauterkrankung, die zu einer Beeinträchtigung des zentralen Sehvermögens führt und häufig eine hohe Rezidivrate aufweist. Die genaue Ätiologie und der pathogenetische Mechanismus sind noch nicht vollständig aufgeklärt, sind aber wahrscheinlich mit einer Hyperpermeabilität der Aderhautkapillaren und einem Versagen des retinalen Pigmentepithels (RPE) verbunden, was zu einer serösen Ablösung der neurosensorischen Netzhaut führt. Die multimodale Bildgebung spielt eine entscheidende Rolle beim diagnostischen Ansatz und der Überwachung von CCS. Glücklicherweise ist der natürliche Krankheitsverlauf i. d. R. selbstlimitierend mit spontaner Auflösung und vollständiger Flüssigkeitsresorption. Einige Patienten können jedoch Rezidive oder anhaltende subretinale Flüssigkeit (chronische CCS) aufweisen, was zu fortschreitender und irreversibler RPE-Atrophie oder Photorezeptorschädigung führt. Um einen dauerhaften Sehverlust zu verhindern, sollte daher eine individuelle Behandlung in Betracht gezogen werden. Jüngste Entwicklungen im diagnostischen und therapeutischen Ansatz haben zu besseren Ergebnissen bei Patienten mit CCS beigetragen. Weitere Studien sind erforderlich, um unser Verständnis von Epidemiologie, Pathogenese, Diagnose und Behandlung zu verbessern, mit erheblichen Auswirkungen auf das Management dieser herausfordernden klinischen Entität. Ziel dieser Übersichtsarbeit ist es, den aktuellen Wissensstand über klinische Merkmale, diagnostische Abklärung und therapeutisches Vorgehen der CCS zusammenzufassen.

Key words

central serous chorioretinopathy - multimodal imaging - photodynamic therapy - anti-VEGF agents

Schlüsselwörter

Chorioretinopathia centralis serosa - multimodale Bildgebung - photodynamische Therapie - Anti-VEGF

Full Text

References

References
1 Spaide RF, Campeas L, Haas A. et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996; 103: 2070-2079 discussion 2079–2080
2 Wang M, Munch IC, Hasler PW. et al. Central serous chorioretinopathy. Acta Ophthalmol (Copenh) 2008; 86: 126-145
3 Semeraro F, Morescalchi F, Russo A. et al. Central Serous Chorioretinopathy: Pathogenesis and Management. Clin Ophthalmol 2019; 13: 2341-2352
4 Haimovici R, Koh S, Gagnon DR. et al. Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004; 111: 244-249
5 Kitzmann AS, Pulido JS, Diehl NN. et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 2008; 115: 169-173
6 Nicholson B, Noble J, Forooghian F. et al. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013; 58: 103-126
7 Desai UR, Alhalel AA, Campen TJ. et al. Central serous chorioretinopathy in African Americans. J Natl Med Assoc 2003; 95: 553-559
8 Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002; 47: 431-448
9 Harada T, Harada K. Six cases of central serous choroidopathy induced by systemic corticosteroid therapy. Doc Ophthalmol 1985; 60: 37-44
10 Wakakura M, Ishikawa S. Central serous chorioretinopathy complicating systemic corticosteroid treatment. Br J Ophthalmol 1984; 68: 329-331
11 Tittl MK, Spaide RF, Wong D. et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999; 128: 63-68
12 Bouzas EA, Scott MH, Mastorakos G. et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993; 111: 1229-1233
13 Cousins L, Rigg L, Hollingsworth D. et al. Qualitative and quantitative assessment of the circadian rhythm of cortisol in pregnancy. Am J Obstet Gynecol 1983; 145: 411-416
14 Kalogeropoulos D, Sung VC, Paschopoulos M. et al. The physiologic and pathologic effects of pregnancy on the human visual system. J Obstet Gynaecol 2019; 39: 1037-1048
15 Chumbley LC, Frank RN. Central serous retinopathy and pregnancy. Am J Ophthalmol 1974; 77: 158-160
16 Šmigelskas K, Žemaitienė N, Julkunen J. et al. Type A behavior pattern is not a predictor of premature mortality. Int J Behav Med 2015; 22: 161-169
17 Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 1986; 84: 799-845
18 Mansuetta CC, Mason 3rd JO, Swanner J. et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol 2004; 137: 1096-1100
19 Michael JC, Pak J, Pulido J. et al. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am J Ophthalmol 2003; 136: 182-185
20 Sun J, Tan J, Wang Z. et al. Effect of catecholamine on central serous chorioretinopathy. J Huazhong Univ Sci Technolog Med Sci 2003; 23: 313-316
21 Yoshioka H, Katsume Y, Akune H. Experimental central serous chorioretinopathy in monkey eyes: fluorescein angiographic findings. Ophthalmologica 1982; 185: 168-178
22 Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010; 149: 361-363
23 Zarnegar A, Ong J, Matsyaraja T. et al. Pathomechanisms in central serous chorioretinopathy: A recent update. Int J Retina Vitreous 2023; 9: 3
24 Ojima Y, Tsujikawa A, Hangai M. et al. Retinal sensitivity measured with the micro perimeter 1 after resolution of central serous chorioretinopathy. Am J Ophthalmol 2008; 146: 77-84
25 Prünte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996; 121: 26-34
26 Spaide RF, Hall L, Haas A. et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996; 16: 203-213
27 Imamura Y, Fujiwara T, Margolis R. et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009; 29: 1469-1473
28 Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. (published correction appears in Am J Ophthalmol 2009; 148(2): 325. Pozonni, Maria C corrected to Pozzoni, Maria C) Am J Ophthalmol 2008; 146: 496-500
29 Okushiba U, Takeda M. [Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography]. Nihon Ganka Gakkai Zasshi 1997; 101: 74-82
30 Uyama M, Matsunaga H, Matsubara T. et al. Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Retina 1999; 19: 12-21
31 Yannuzzi LA, Slakter JS, Gross NE. et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23: 288-298
32 Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006; 27: 413-426
33 Sandle GI, McGlone F. Acute effects of dexamethasone on cation transport in colonic epithelium. Gut 1987; 28: 701-706
34 Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol 2004; 2: 1-12
35 Yoshioka H, Katsume Y. [Studies on experimental central serous chorioretinopathy. A light and electron microscopy]. Nihon Ganka Gakkai Zasshi 1982; 86: 738-749
36 Caccavale A, Imparato M, Romanazzi F. et al. A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med Hypotheses 2009; 73: 435-437
37 Caccavale A, Romanazzi F, Imparato M. et al. Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol 2011; 5: 239-243
38 Iijima H, Iida T, Murayama K. et al. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol 1999; 127: 477-478
39 Dansingani KK, Balaratnasingam C, Naysan J. et al. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 2016; 36: 499-516
40 Cheung CMG, Lee WK, Koizumi H. et al. Pachychoroid disease. Eye (Lond) 2019; 33: 14-33
41 Spaide RF, Gemmy Cheung CM, Matsumoto H. et al. Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res 2022; 86: 100973
42 Spaide RF. The Ambiguity of Pachychoroid. Retina 2021; 41: 231-237
43 Negi A, Marmor MF. Experimental serous retinal detachment and focal pigment epithelial damage. Arch Ophthalmol 1984; 102: 445-449
44 Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 1986; 224: 321-324
45 Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 2011; 22: 166-173
46 Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond) 2010; 24: 1743-1756
47 Fujimoto H, Gomi F, Wakabayashi T. et al. Morphologic changes in acute central serous chorioretinopathy evaluated by fourier-domain optical coherence tomography. Ophthalmology 2008; 115: 1494-1500.e2
48 Gupta P, Gupta V, Dogra MR. et al. Morphological changes in the retinal pigment epithelium on spectral-domain OCT in the unaffected eyes with idiopathic central serous chorioretinopathy. Int Ophthalmol 2010; 30: 175-181
49 Garg SP, Dada T, Talwar D. et al. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol 1997; 81: 962-964
50 Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003; 110: 698-703
51 Sun J, Tan J, Wang Z. et al. Effect of catecholamine on central serous chorioretinopathy. J Huazhong Univ Sci Technolog Med Sci 2003; 23: 313-316
52 Sakaue M, Hoffman BB. Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest 1991; 88: 385-389
53 Oikarinen AI, Uitto J, Oikarinen J. Glucocorticoid action on connective tissue: from molecular mechanisms to clinical practice. Med Biol 1986; 64: 221-230
54 Bastl CP. Regulation of cation transport by low doses of glucocorticoids in in vivo adrenalectomized rat colon. J Clin Invest 1987; 80: 348-356
55 Sandle GI, McGlone F. Acute effects of dexamethasone on cation transport in colonic epithelium. Gut 1987; 28: 701-706
56 Smith PR, Benos DJ. Epithelial Na+ channels. Annu Rev Physiol 1991; 53: 509-530
57 Arndt C, Sari A, Ferre M. et al. Electrophysiological effects of corticosteroids on the retinal pigment epithelium. Invest Ophthalmol Vis Sci 2001; 42: 472-475
58 Baumal CR, Martidis A, Truong SN. Central serous chorioretinopathy associated with periocular corticosteroid injection treatment for HLA-B27-associated iritis. Arch Ophthalmol 2004; 122: 926-928
59 Imasawa M, Ohshiro T, Gotoh T. et al. Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol Scand 2005; 83: 132-133
60 Kocabora MS, Durmaz S, Kandemir N. Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1783-1786
61 Ahnoux-Zabsonre A, Quaranta M, Mauget-Faÿsse M. [Prevalence of Helicobacter pylori in central serous chorioretinopathy and diffuse retinal epitheliopathy: a complementary study]. J Fr Ophtalmol 2004; 27: 1129-1133
62 Asensio-Sánchez VM, Rodríguez-Delgado B, García-Herrero E. et al. [Central serous chorioretinopathy as an extradigestive manifestation of Helicobacter pylori gastric infection]. Arch Soc Esp Oftalmol 2008; 83: 177-182
63 Cotticelli L, Borrelli M, DʼAlessio AC. et al. Central serous chorioretinopathy and Helicobacter pylori . Eur J Ophthalmol 2006; 16: 274-278
64 Giusti C. [Central serous chorioretinopathy: a new extragastric manifestation of Helicobacter pylori?: Analysis of a clinical case]. Clin Ter 2001; 152: 393-397
65 Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L. et al. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 2011; 17: 99-103
66 Byrne MF, Kerrigan SW, Corcoran PA. et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003; 124: 1846-1854
67 Giusti C. Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis. Med Hypotheses 2004; 63: 524-527
68 Amalric P, Gourinat P, Rebiere P. Is central serous choroiditis sometimes hereditary?. Bull Soc Ophtalmol Fr 1971; 71: 163-168
69 Haik GM, Perez LF, Murtagh JJ. Central serous retinopathy. Consecutive development in daughter and mother. Am J Ophthalmol 1968; 65: 612-615
70 Lin E, Arrigg PG, Kim RY. Familial central serous choroidopathy. Graefes Arch Clin Exp Ophthalmol 2000; 238: 930-931
71 Oosterhuis JA. Familial central serous retinopathy. Graefes Arch Clin Exp Ophthalmol 1996; 234: 337-341
72 Park DW, Schatz H, Gaffney MM. et al. Central serous chorioretinopathy in two families. Eur J Ophthalmol 1998; 8: 42-47
73 Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic central serous chorioretinopathy. Ophthalmologica 2001; 215: 183-187
74 Lim JW, Kim MU, Shin MC. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 2010; 30: 1465-1471
75 Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 2011; 31: 1937-1943
76 Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307
77 Wang Z, Xin Z, Yang J. et al. Choriocapillaris Ischemia at the Leakage Point of Patients With Acute Central Serous Chorioretinopathy. Front Med (Lausanne) 2021; 8: 675876
78 Salehi M, Wenick AS, Law HA. et al. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev 2015; (12) CD011841
79 Daruich A, Matet A, Dirani A. et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res 2015; 48: 82-118
80 Singh SR, Matet A, van Dijk EHC. et al. Discrepancy in current central serous chorioretinopathy classification. Br J Ophthalmol 2019; 103: 737-742
81 Piccolino FC, de la Longrais RR, Ravera G. et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 2005; 139: 87-99
82 Reibaldi M, Cardascia N, Longo A. et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010; 149: 307-315.e2
83 Shin JY, Woo SJ, Yu HG. et al. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2011; 31: 119-126
84 Chan WM, Lai TY, Lai RY. et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 2008; 28: 85-93
85 Gass JD. Bullous retinal detachment. An unusual manifestation of idiopathic central serous choroidopathy. Am J Ophthalmol 1973; 75: 810-821
86 Sahu DK, Namperumalsamy P, Hilton GF. et al. Bullous variant of idiopathic central serous chorioretinopathy. Br J Ophthalmol 2000; 84: 485-492
87 Otsuka S, Ohba N, Nakao K. A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina 2002; 22: 25-32
88 Semeraro F, Morescalchi F, Russo A. et al. Central Serous Chorioretinopathy: Pathogenesis and Management. Clin Ophthalmol 2019; 13: 2341-2352
89 Montero JA, Ruiz-Moreno JM. Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy. Br J Ophthalmol 2005; 89: 562-564
90 Maruko I, Iida T, Sugano Y. et al. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina 2011; 31: 1603-1608
91 Kim SW, Oh J, Kwon SS. et al. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. Retina 2011; 31: 1904-1911
92 Maruko I, Iida T, Sugano Y. et al. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010; 117: 1792-1799
93 Maruko I, Iida T, Sugano Y. et al. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina 2011; 31: 1921-1927
94 Matsumoto H, Kishi S, Otani T. et al. Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 2008; 145: 162-168
95 Maruko I, Iida T, Ojima A. et al. Subretinal dot-like precipitates and yellow material in central serous chorioretinopathy. Retina 2011; 31: 759-765
96 Kon Y, Iida T, Maruko I. et al. The optical coherence tomography-ophthalmoscope for examination of central serous chorioretinopathy with precipitates. Retina 2008; 28: 864-869
97 Matsumoto H, Kishi S, Sato T. et al. Fundus autofluorescence of elongated photoreceptor outer segments in central serous chorioretinopathy. Am J Ophthalmol 2011; 151: 617-623.e1
98 Spaide RF, Klancnik jr. JM. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 2005; 112: 825-833
99 Mitarai K, Gomi F, Tano Y. Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1415-1420
100 Oh J, Smiddy WE, Flynn jr HW. et al. Photoreceptor inner/outer segment defect imaging by spectral domain OCT and visual prognosis after macular hole surgery. Invest Ophthalmol Vis Sci 2010; 51: 1651-1658
101 Oishi A, Otani A, Sasahara M. et al. Photoreceptor integrity and visual acuity in cystoid macular oedema associated with retinitis pigmentosa. Eye (Lond) 2009; 23: 1411-1416
102 Kim SW, Oh J, Huh K. Correlations among various functional and morphological tests in resolved central serous chorioretinopathy. Br J Ophthalmol 2012; 96: 350-355
103 Matsumoto H, Sato T, Kishi S. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am J Ophthalmol 2009; 148: 105-110.e1
104 Ojima Y, Hangai M, Sasahara M. et al. Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using high-speed optical coherence tomography. Ophthalmology 2007; 114: 2197-2207
105 Jia Y, Bailey ST, Wilson DJ. et al. Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. Ophthalmology 2014; 121: 1435-1444
106 Quaranta-El Maftouhi M, El Maftouhi A, Eandi CM. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol 2015; 160: 581-587.e1
107 Spaide RF, Klancnik jr JM, Cooney MJ. Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol 2015; 133: 45-50
108 Cakir B, Reich M, Lang S. et al. OCT Angiography of the Choriocapillaris in Central Serous Chorioretinopathy: A Quantitative Subgroup Analysis. Ophthalmol Ther 2019; 8: 75-86
109 Reich M, Böhringer D, Cakir B. et al. Longitudinal Analysis of the Choriocapillaris Using Optical Coherence Tomography Angiography Reveals Subretinal Fluid as a Substantial Confounder in Patients with Acute Central Serous Chorioretinopathy. Ophthalmol Ther 2019; 8: 599-610
110 Delori FC, Dorey CK, Staurenghi G. et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995; 36: 718-729
111 Eldred GE, Katz ML. Fluorophores of the human retinal pigment epithelium: separation and spectral characterization. Exp Eye Res 1988; 47: 71-86
112 Matsumoto H, Kishi S, Sato T. et al. Fundus autofluorescence of elongated photoreceptor outer segments in central serous chorioretinopathy. Am J Ophthalmol 2011; 151: 617-623 e1
113 Imamura Y, Fujiwara T, Spaide RF. Fundus autofluorescence and visual acuity in central serous chorioretinopathy. Ophthalmology 2011; 118: 700-705
114 Yamada K, Hayasaka S, Setogawa T. Fluorescein-angiographic patterns in patients with central serous chorioretinopathy at the initial visit. Ophthalmologica 1992; 205: 69-76
115 Iyer PG, Schwartz SG, Russell JF. et al. Central Serous Chorioretinopathy: Multimodal Imaging and Management Options. Case Rep Ophthalmol Med 2020; 2020: 8890404
116 Kitaya N, Nagaoka T, Hikichi T. et al. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 2003; 87: 709-712
117 Maltsev DS, Kulikov AN, Chhablani J. Topography-guided identification of leakage point in central serous chorioretinopathy: a base for fluorescein angiography-free focal laser photocoagulation. Br J Ophthalmol 2018; 102: 1218-1225
118 Kishi S, Matsumoto H. A new insight into pachychoroid diseases: Remodeling of choroidal vasculature. Graefes Arch Clin Exp Ophthalmol 2022; 260: 3405-3417
119 Matsumoto H, Hoshino J, Mukai R. et al. Pulsation of anastomotic vortex veins in pachychoroid spectrum diseases. Sci Rep 2021; 11: 14942
120 Fujita K, Yuzawa M, Mori R. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Retina 2011; 31: 772-778
121 Reibaldi M, Boscia F, Avitabile T. et al. Functional retinal changes measured by microperimetry in standard-fluence vs. low-fluence photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2011; 151: 953-960.e2
122 Senturk F, Karacorlu M, Ozdemir H. et al. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 2011; 151: 303-309.e1
123 Ozdemir H, Karacorlu SA, Senturk F. et al. Assessment of macular function by microperimetry in unilateral resolved central serous chorioretinopathy. Eye (Lond) 2008; 22: 204-208
124 Marmor MF, Tan F. Central serous chorioretinopathy: bilateral multifocal electroretinographic abnormalities. Arch Ophthalmol 1999; 117: 184-188
125 Moschos M, Brouzas D, Koutsandrea C. et al. Assessment of central serous chorioretinopathy by optical coherence tomography and multifocal electroretinography. Ophthalmologica 2007; 221: 292-298
126 Vajaranant TS, Szlyk JP, Fishman GA. et al. Localized retinal dysfunction in central serous chorioretinopathy as measured using the multifocal electroretinogram. Ophthalmology 2002; 109: 1243-1250
127 Suzuki K, Hasegawa S, Usui T. et al. Multifocal Electroretinogram in Central Serous Chorioretinopathy. Jpn J Ophthalmol 2000; 44: 571
128 Suzuki K, Hasegawa S, Usui T. et al. Multifocal electroretinogram in patients with central serous chorioretinopathy. Jpn J Ophthalmol 2002; 46: 308-314
129 Yip YW, Ngai JW, Fok AC. et al. Correlation between functional and anatomical assessments by multifocal electroretinography and optical coherence tomography in central serous chorioretinopathy. Doc Ophthalmol 2010; 120: 193-200
130 Lai TY, Lai RY, Ngai JW. et al. First and second-order kernel multifocal electroretinography abnormalities in acute central serous chorioretinopathy. Doc Ophthalmol 2008; 116: 29-40
131 Wu ZH, Lai RY, Yip YW. et al. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 2011; 31: 1378-1386
132 Ooto S, Hangai M, Sakamoto A. et al. High-resolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy. Ophthalmology 2010; 117: 1800-1809.e2
133 Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina 1987; 7: 111-131
134 Spahn C, Wiek J, Burger T. et al. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol 2003; 87: 704-708
135 Leveque TK, Yu L, Musch DC. et al. Central serous chorioretinopathy and risk for obstructive sleep apnea. Sleep Breath 2007; 11: 253-257
136 Kloos P, Laube I, Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1225-1228
137 Fraunfelder FW, Fraunfelder FT. Central serous chorioretinopathy associated with sildenafil. Retina 2008; 28: 606-609
138 French DD, Margo CE. Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina 2010; 30: 271-274
139 Carvalho-Recchia CA, Yannuzzi LA, Negrão S. et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002; 109: 1834-1837
140 Zakir SM, Shukla M, Simi ZU. et al. Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy. Indian J Ophthalmol 2009; 57: 419-422
141 Jampol LM, Weinreb R, Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies. Ophthalmology 2002; 109: 1765-1766
142 Abdelhakeem E, El-Nabarawi M, Shamma R. Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends. Br J Clin Pharmacol 2022; 88: 2665-2672
143 Wang SK, Sun P, Tandias RM. et al. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials. Ophthalmol Retina 2019; 3: 154-160
144 Duan J, Zhang Y, Zhang M. Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis. Eye (Lond) 2021; 35: 1102-1110
145 Lotery A, Sivaprasad S, OʼConnell A. et al. Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT. Southampton (UK): NIHR Journals Library; 2021
146 Wolfensberger TJ, Chiang RK, Takeuchi A. et al. Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 2000; 238: 76-80
147 Pikkel J, Beiran I, Ophir A. et al. Acetazolamide for central serous retinopathy. Ophthalmology 2002; 109: 1723-1725
148 Yamada R, Yamada S, Ishii A. et al. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy. Nihon Ganka Gakkai Zasshi 1993; 97: 955-960
149 Caccavale A, Romanazzi F, Imparato M. et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol 2010; 4: 899-903
150 Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol 2010; 24: 155-158
151 Bae SH, Heo JW, Kim C. et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 2011; 152: 784-792.e2
152 Arevalo JF, Espinoza JV. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2011; 249: 1159-1166
153 Inoue M, Kadonosono K, Watanabe Y. et al. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy. Ophthalmologica 2011; 225: 37-40
154 Lee ST, Adelman RA. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab. J Ocul Pharmacol Ther 2011; 27: 611-614
155 Li XJ, Zhang JS. Intravitreal bevacizumab injection for chronic central serous chorioretinopathy. Chin Med J (Engl) 2010; 123: 2145-2147
156 Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2011; 249: 969-974
157 Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010; 30: 100-106
158 Schaal KB, Hoeh AE, Scheuerle A. et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009; 19: 613-617
159 Seong HK, Bae JH, Kim ES. et al. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica 2009; 223: 343-347
160 Torres-Soriano ME, García-Aguirre G, Kon-Jara V. et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 2008; 246: 1235-1239
161 Artunay O, Yuzbasioglu E, Rasier R. et al. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 2010; 35: 91-98
162 Lee JY, Chae JB, Yang SJ. et al. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol 2011; 89: e293-e294
163 Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009; 54: 372-400
164 Chan WM, Lai TY, Liu DT. et al. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007; 143: 977-983
165 Mandal S, Sinha S, Abbas Z. et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization complicating active central serous chorioretinopathy. Indian J Ophthalmol 2011; 59: 338-339
166 Montero JA, Ruiz-Moreno JM, Fernandez-Muñoz M. Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy. Eur J Ophthalmol 2011; 21: 503-505
167 Pikkel J, Rumelt S. Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy. Eur J Ophthalmol 2012; 22: 488-491
168 Konstantinidis L, Mantel I, Zografos L. et al. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. Eur J Ophthalmol 2010; 20: 955-958
169 Carneiro AM, Silva RM, Veludo MJ. et al. Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia. Ophthalmologica 2011; 225: 81-88
170 Mitsui Y, Matsubara M, Kanagawa M. [Xenon light-exposure as a treatment of central serous retinopathy (a preliminary report)]. Nihon Ganka Kiyo 1969; 20: 291-294
171 Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1979; 63: 674-677
172 Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983; 95: 457-466
173 Burumcek E, Mudun A, Karacorlu S. et al. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997; 104: 616-622
174 Brancato R, Scialdone A, Pece A. et al. Eight-year follow-up of central serous chorioretinopathy with and without laser treatment. Graefes Arch Clin Exp Ophthalmol 1987; 225: 166-168
175 Gilbert CM, Owens SL, Smith PD. et al. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 1984; 68: 815-820
176 Yannuzzi LA, Slakter JS, Kaufman SR. et al. Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 1992; 2: 103-114
177 Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina 2003; 23: 235-237
178 Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45: 195-214
179 Schmidt-Erfurth U, Michels S, Barbazetto I. et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002; 43: 830-841
180 Chan WM, Lam DSC, Lai TYY. et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003; 87: 1453-1458
181 Cardillo Piccolino F, Eandi CM, Ventre L. et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23: 752-763
182 Taban M, Boyer DS, Thomas EL. et al. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004; 137: 1073-1080
183 Chan WM, Lai TY, Lai RY. et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008; 115: 1756-1765
184 Moon JW, Yu HG, Kim TW. et al. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1315-1323
185 Koytak A, Erol K, Coskun E. et al. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 2010; 30: 1698-1703
186 Lai TY, Chan WM, Li H. et al. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006; 90: 869-874
187 Reibaldi M, Cardascia N, Longo A. et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010; 149: 307-315.e2
188 Reibaldi M, Boscia F, Avitabile T. et al. Low-fluence photodynamic therapy in longstanding chronic central serous chorioretinopathy with foveal and gravitational atrophy. Eur J Ophthalmol 2009; 19: 154-158
189 Williams MA, Mulholland C, Silvestri G. Photodynamic therapy for central serous chorioretinopathy using a reduced dose of verteporfin. Can J Ophthalmol 2008; 43: 123
190 Kim SW, Oh J, Oh IK. et al. Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2009; 40: 300-303
191 Semeraro F, Romano MR, Danzi P. et al. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol 2012; 56: 608-612
192 Nicoló M, Eandi CM, Alovisi C. et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2014; 157: 1033-1037.e2
193 van Dijk EHC, Fauser S, Breukink MB. et al. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology 2018; 125: 1547-1555
194 van Rijssen TJ, van Dijk EHC, Tsonaka R. et al. Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial. Am J Ophthalmol 2022; 233: 101-110
195 Feenstra HMA, van Dijk EHC, van Rijssen TJ. et al. Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3. Graefes Arch Clin Exp Ophthalmol 2023; 261: 659-668
196 Vujosevic S, Bottega E, Casciano M. et al. Microperimetry and fundus autofluorescence in diabetic macular edema. Retina 2010; 30: 908-916
197 Luttrull JK, Chang DB, Margolis BWL. et al. Laser resensitization of medically unresponsive neovascular age-related macular degeneration: efficacy and implications. Retina 2015; 35: 1184-1194
198 Luttrull JK. Low-intensity/high-density subthreshold diode micropulse laser for central serous chorioretinopathy. Retina 2016; 36: 1658-1663
199 Kregel KC. Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J Appl Physiol (1985) 2002; 92: 2177-2186
200 Scholz P, Altay L, Fauser S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond) 2016; 30: 1371-1377
201 Verma L, Sinha R, Venkatesh P. et al. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]. BMC Ophthalmol 2004; 4: 15
202 Ricci F, Missiroli F, Cerulli L. Indocyanine green dye-enhanced micropulsed diode laser: a novel approach to subthreshold RPE treatment in a case of central serous chorioretinopathy. Eur J Ophthalmol 2004; 14: 74-82
203 Ricci F, Missiroli F, Regine F. et al. Indocyanine green enhanced subthreshold diode-laser micropulse photocoagulation treatment of chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 597-607
204 Hussain N, Khanna R, Hussain A. et al. Transpupillary thermotherapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1045-1051
205 Shukla D, Kolluru C, Vignesh TP. et al. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye (Lond) 2008; 22: 100-106
206 Wei SY, Yang CM. Transpupillary thermotherapy in the treatment of central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2005; 36: 412-415
207 Mudvari SS, Goff MJ, Fu AD. et al. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina 2007; 27: 1168-1173
208 Liegl R, Ulbig MW. Central serous chorioretinopathy. Ophthalmologica 2014; 232: 65-76
209 Baran NV, Gürlü VP, Esgin H. Long-term macular function in eyes with central serous chorioretinopathy. Clin Experiment Ophthalmol 2005; 33: 369-372
210 Loo RH, Scott IU, Flynn HW. et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002; 22: 19-24
211 Eandi CM, Chung JE, Cardillo-Piccolino F. et al. Optical coherence tomography in unilateral resolved central serous chorioretinopathy. Retina 2005; 25: 417-421
212 Furuta M, Iida T, Kishi S. Foveal thickness can predict visual outcome in patients with persistent central serous chorioretinopathy. Ophthalmologica 2009; 223: 28-31